Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
DVA · against 156 other Healthcare companies of similar size
Ranked #10 of 157 · scores higher than 94% of peers
Bars: peers in each 10-point band of the valuation score15 peers with a valuation score of 90–100, including DVA · Click a bar to see the companies
Mainly thanks to its free cash flow yield, earnings yield and EBITDA yield, which are stronger than most Healthcare peers.
| Metric | DVA | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 155 reported | 6.4% | 2.6% | 90% | 30% | |
| EBITDA yieldHigher is better · 157 reported | 10.8% | 4.8% | 88% | 50% | |
| Free cash flow yieldHigher is better · 91 reported | 13.9% | 2.5% | 96% | 20% | |
| Book yieldHigher is better · 155 reported | -6.6% | 19.6% | 1% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 2 | 89.5B HKD (≈$11.5B) | 98 | 67 | |
| 3 | 10.4B USD | 96 | 64 | |
| 4 | 80.2B CNY (≈$11.2B) | 95 | 76 | |
| 4 | 21.5B USD | 95 | 60 | |
| 6 | 11.6B USD | 94 | 58 | |
| 6 | 68.0B BRL (≈$12.2B) | 94 | 67 | |
| 8 | 1.09T JPY (≈$7.4B) | 93 | 75 | |
| 8 | 5.8B USD | 93 | 64 | |
| 10 | 11.6B USD | 92 | 57 | |
| 10 | 14.4B USD | 92 | 71 | |
| 12 | 1.30T JPY (≈$8.8B) | 91 | 71 | |
| 12 | 884.9B JPY (≈$6.0B) | 91 | 61 | |
| 14 | 47.7B CNY (≈$6.7B) | 90 | 64 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score